The last month of summer saw several hires, including a lead for Worldwide Clinical Trials’ Japan operations, CEO appointments at CordenPharma and LabConnect, and Altasciences’ new CSO, who joins the company from Syneos.
908 Devices launches Rebel, a bioprocess analyzer, enabling researchers to conduct their own cell culture media analysis to accelerate process development ‘by weeks’.
NHS GDE Trust Worcestershire Health and Care collaborates with Clinithink to better manage its clinical data through the latter’s ‘natural language processing’ platform.
Researchers develop organ-on-an-electronic-chip platform to explore the electrophysiology of iPSC-derived cardiomyocytes and understand how the heart communicates.
Themis obtains an exclusive licence from Merck to develop vaccine candidates with an undisclosed indication, using its measles virus vector-based platform.
As summer heated up, the pharmaceutical industry saw major developments in preclinical models from new software to 3D-printed tissue, all in the name of drug development.
Researchers show miniature livers can develop steatohepatitis and fibrosis, pointing to potential for personalized hepatic drug discovery and toxicity platforms.
Schrödinger secures further funding, extends collaboration with Morphic Therapeutic on computational discovery platform for oral integrin drugs for the second time.
Engineered cardiac tissues generated using Tara Biosystems' heart-on-a-chip system predict how patients will respond to a range of drugs, as demonstrated in a recent study with GSK.
SGS’ OneVision initiative is working to standardize record-keeping across the global life sciences industry in an aim to accelerate laboratory testing, development, and eliminate paper-based systems.
Boehringer Ingelheim and the University of Texas MD Anderson Cancer Center entered a multi-year partnership to conduct collaborative translational research for lung and GI cancers.
